Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

eftozanermin alfa (ABBV-621)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AbbVie, Apogenix

Drug class:

TRAIL R2 agonist, TRAIL R1 agonist

Related drugs:

IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax + ABBV-621 Sensitive: C3 – Early Trials venetoclax + ABBV-621 Sensitive : C3	venetoclax + ABBV-621 Sensitive: C3 – Early Trials venetoclax + ABBV-621 Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax + ABBV-621 Sensitive: C3 – Early Trials venetoclax + ABBV-621 Sensitive : C3	venetoclax + ABBV-621 Sensitive: C3 – Early Trials venetoclax + ABBV-621 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax + ABBV-621 Sensitive: C4 – Case Studies venetoclax + ABBV-621 Sensitive : C4	venetoclax + ABBV-621 Sensitive: C4 – Case Studies venetoclax + ABBV-621 Sensitive : C4